R. Hanna, M.D., et al. EDIT-301 Shows Promising Preliminary Safety and Efficacy Results in the Phase I/II Clinical Trial (RUBY) of Patients with Severe Sickle Cell Disease Using Highly Specific and Efficient AsCas12a Enzyme. Presented at the European Hematology Association Hybrid Congress. June 8 -16, 2023.